Prostatype Genomics AB (publ) (PGABF)
OTCMKTS · Delayed Price · Currency is USD
0.0850
-0.2734 (-76.28%)
At close: Jan 7, 2026

Prostatype Genomics AB Income Statement

Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Operating Revenue
0.721.923.730.682.512.38
Other Revenue
-0----0.63
0.721.923.730.682.513.01
Revenue Growth (YoY)
-82.63%-48.55%445.83%-72.78%-16.56%6.28%
Cost of Revenue
21.822.3619.8313.498.497.61
Gross Profit
-21.08-20.44-16.1-12.81-5.98-4.6
Selling, General & Admin
15.7515.7118.110.397.985.95
Research & Development
2.212.213.233.511.491.54
Other Operating Expenses
0.370.52-0.060.080.010.06
Operating Expenses
20.4420.4223.1415.889.577.65
Operating Income
-41.52-40.85-39.25-28.69-15.55-12.25
Interest Expense
-1.08-1.68-1.54-0.4-0.08-1.44
Interest & Investment Income
0.040.040---
Currency Exchange Gain (Loss)
-2.751.44-0.65---
Other Non Operating Income (Expenses)
00--0--
Pretax Income
-45.31-41.05-41.44-29.09-15.63-13.69
Net Income
-45.31-41.05-41.44-29.09-15.63-13.69
Net Income to Common
-45.31-41.05-41.44-29.09-15.63-13.69
Shares Outstanding (Basic)
101000-
Shares Outstanding (Diluted)
101000-
Shares Change (YoY)
2474.32%1645.51%343.99%28.75%--
EPS (Basic)
-4.76-29.10-512.68-1597.92-1105.51-
EPS (Diluted)
-4.76-29.10-512.68-1597.92-1105.51-
Free Cash Flow
-39.09-44.99-29.21-27.69-16.08-11.27
Free Cash Flow Per Share
-4.11-31.89-361.46-1521.34-1137.23-
Gross Margin
-----238.34%-152.99%
Operating Margin
-5806.85%-2130.03%-1052.76%-4200.44%-619.54%-407.31%
Profit Margin
-6336.50%-2140.30%-1111.45%-4258.71%-622.79%-455.05%
Free Cash Flow Margin
-5467.27%-2345.88%-783.61%-4054.61%-640.66%-374.54%
EBITDA
-41.27-40.73-39.23-28.64-15.46-12.15
D&A For EBITDA
0.250.120.020.050.090.1
EBIT
-41.52-40.85-39.25-28.69-15.55-12.25
Revenue as Reported
0.721.983.790.682.522.96
Source: S&P Global Market Intelligence. Standard template. Financial Sources.